-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lung cancer is a very common malignant tumor, and the incidence of lung cancer in China is high
.
According to the pathological type, lung cancer can be divided into small cell lung cancer and non-small cell lung cancer.
Among them, non-small cell lung cancer is a common type of lung cancer, and the incidence rate accounts for about 85% of the total number of lung cancers
.
In recent years, with the progress of medical research, the research on non-small cell lung cancer has also deepened, and various specific molecularly targeted drugs have gradually been born
.
However, for patients with non-small cell lung cancer, there is still a large unmet need for treatment
.
For the majority of patient groups, the market potential of targeted drugs for non-small cell lung cancer is huge
.
Data show that in 2019, the market size of targeted drugs for non-small cell lung cancer in China has exceeded 20 billion yuan
.
The industry expects that with the advancement of medical insurance reform and the continuous emergence of domestic innovative drugs, the availability of targeted drugs for non-small cell lung cancer will continue to increase, and the domestic market demand and development potential will be huge, which is expected to reach 86.
7 billion yuan in 2024.
And by 2030, it will further break through the 180 billion yuan mark
.
From the perspective of the market structure, the current domestic non-small cell lung cancer targeted drug market is extremely competitive, and domestic and foreign pharmaceutical companies are actively deploying in this field
.
On January 5 this year, Novartis' non-small cell lung cancer drug "capmatinib" announced that it has successfully landed in the Hainan Boao Lecheng International Medical Tourism Pilot Zone, for the metastatic MET exon 14 (METex14) skipping mutation in mainland China Non-small cell lung cancer patients bring global synchronization and precision treatment
.
With the emergence of the potential of the domestic market, the layout of foreign-funded enterprises in the Chinese market will also be further deepened
.
With the improvement of the strength of local pharmaceutical companies, many companies are gradually targeting the field of non-small cell lung cancer, and continue to tap a larger market
.
For example, on February 17, CStone Pharmaceuticals-B announced that the selective RET inhibitor pratinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer with positive transfection and rearrangement gene fusion, and advanced or metastatic RET mutation New drug applications for medullary thyroid cancer and RET fusion-positive advanced or metastatic thyroid cancer refractory to radioactive iodine (if radioactive iodine is applicable) have been accepted by the Food and Drug Administration of the Taiwan Ministry of Health and Welfare
.
Pratinib is a potent and selective RET inhibitor developed by CStone partner Blueprint Medicines Corporation, the announcement said
.
With the active R&D and efforts of domestic and foreign pharmaceutical companies, a number of lung cancer drugs have been launched in China, bringing more choices for the treatment of lung cancer patients
.
Data show that by 2021, 23 targeted drugs for non-small cell lung cancer have been launched in China, 80% of which are focused on EGFR, PD-(L)1 and ALK targets
.
It is worth mentioning that due to the relatively expensive lung cancer treatment drugs, the national medical insurance adjustment has also continuously included lung cancer treatment drugs to reduce the burden on patients
.
It is understood that at least half of the drugs in the lung cancer market (4 PD-1, 10 EGFR) have entered the medical insurance catalog
.
In the new round of medical insurance, the oral tumor-targeted drug dacomitinib successfully passed the negotiation of the medical insurance catalogue and was included in the new version of the national medical insurance catalogue
.
From January 1, 2022, Dacomitinib has been able to implement the unified drug price and medical insurance reimbursement policy through the "dual channels" of designated medical institutions and designated retail pharmacies, which will greatly reduce the burden of drug treatment for NSCLC patients with lung cancer
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to the pathological type, lung cancer can be divided into small cell lung cancer and non-small cell lung cancer.
Among them, non-small cell lung cancer is a common type of lung cancer, and the incidence rate accounts for about 85% of the total number of lung cancers
.
In recent years, with the progress of medical research, the research on non-small cell lung cancer has also deepened, and various specific molecularly targeted drugs have gradually been born
.
However, for patients with non-small cell lung cancer, there is still a large unmet need for treatment
.
For the majority of patient groups, the market potential of targeted drugs for non-small cell lung cancer is huge
.
Data show that in 2019, the market size of targeted drugs for non-small cell lung cancer in China has exceeded 20 billion yuan
.
The industry expects that with the advancement of medical insurance reform and the continuous emergence of domestic innovative drugs, the availability of targeted drugs for non-small cell lung cancer will continue to increase, and the domestic market demand and development potential will be huge, which is expected to reach 86.
7 billion yuan in 2024.
And by 2030, it will further break through the 180 billion yuan mark
.
From the perspective of the market structure, the current domestic non-small cell lung cancer targeted drug market is extremely competitive, and domestic and foreign pharmaceutical companies are actively deploying in this field
.
On January 5 this year, Novartis' non-small cell lung cancer drug "capmatinib" announced that it has successfully landed in the Hainan Boao Lecheng International Medical Tourism Pilot Zone, for the metastatic MET exon 14 (METex14) skipping mutation in mainland China Non-small cell lung cancer patients bring global synchronization and precision treatment
.
With the emergence of the potential of the domestic market, the layout of foreign-funded enterprises in the Chinese market will also be further deepened
.
With the improvement of the strength of local pharmaceutical companies, many companies are gradually targeting the field of non-small cell lung cancer, and continue to tap a larger market
.
For example, on February 17, CStone Pharmaceuticals-B announced that the selective RET inhibitor pratinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer with positive transfection and rearrangement gene fusion, and advanced or metastatic RET mutation New drug applications for medullary thyroid cancer and RET fusion-positive advanced or metastatic thyroid cancer refractory to radioactive iodine (if radioactive iodine is applicable) have been accepted by the Food and Drug Administration of the Taiwan Ministry of Health and Welfare
.
Pratinib is a potent and selective RET inhibitor developed by CStone partner Blueprint Medicines Corporation, the announcement said
.
With the active R&D and efforts of domestic and foreign pharmaceutical companies, a number of lung cancer drugs have been launched in China, bringing more choices for the treatment of lung cancer patients
.
Data show that by 2021, 23 targeted drugs for non-small cell lung cancer have been launched in China, 80% of which are focused on EGFR, PD-(L)1 and ALK targets
.
It is worth mentioning that due to the relatively expensive lung cancer treatment drugs, the national medical insurance adjustment has also continuously included lung cancer treatment drugs to reduce the burden on patients
.
It is understood that at least half of the drugs in the lung cancer market (4 PD-1, 10 EGFR) have entered the medical insurance catalog
.
In the new round of medical insurance, the oral tumor-targeted drug dacomitinib successfully passed the negotiation of the medical insurance catalogue and was included in the new version of the national medical insurance catalogue
.
From January 1, 2022, Dacomitinib has been able to implement the unified drug price and medical insurance reimbursement policy through the "dual channels" of designated medical institutions and designated retail pharmacies, which will greatly reduce the burden of drug treatment for NSCLC patients with lung cancer
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
